Sanders Morris Harris LLC Cue Biopharma, Inc. Transaction History

Sanders Morris Harris LLC

$585 Million
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 13, 2023	BUY	$2.23 - $4.69 $772,052 - $1.62 Million	346,212 New	346,212 $796,000
Q2 2023 Jul 10, 2023	BUY	$3.11 - $4.91 $175,466 - $277,022	56,420 New	56,420 $205,000
Q4 2022 Jan 12, 2023	SELL	$2.39 - $3.95 $1.89 Million - $3.13 Million	-791,628 Reduced 93.35%	56,420 $0
Q3 2022 Oct 07, 2022	BUY	$2.23 - $3.37 $249,394 - $376,887	111,836 Added 15.19%	848,048 $2.02 Million
Q2 2022 Jul 11, 2022	SELL	$2.49 - $5.92 $340,654 - $809,909	-136,809 Reduced 15.67%	736,212 $1.8 Million
Q1 2022 Apr 11, 2022	BUY	$4.41 - $12.28 $2.27 Million - $6.31 Million	513,908 Added 143.1%	873,021 $4.26 Million
Q4 2021 Feb 02, 2022	BUY	$10.86 - $17.85 $579,717 - $952,850	53,381 Added 17.46%	359,113 $4.42 Million
Q3 2021 Oct 13, 2021	BUY	$10.06 - $15.3 $581,548 - $884,462	57,808 Added 23.32%	305,732 $4.1 Million
Q2 2021 Jul 13, 2021	SELL	$10.9 - $14.53 $1.14 Million - $1.52 Million	-104,610 Reduced 29.67%	247,924 $2.77 Million
Q1 2021 Apr 19, 2021	BUY	$11.2 - $16.09 $10,640 - $15,285	950 Added 0.27%	352,534 $4.39 Million
Q1 2021 Apr 14, 2021	BUY	$11.2 - $16.09 $1.77 Million - $2.54 Million	157,993 Added 81.61%	351,584 $4.37 Million
Q4 2020 Jan 26, 2021	BUY	$11.12 - $16.4 $568,910 - $839,040	51,161 Added 35.92%	193,591 $2.45 Million
Q3 2020 Oct 16, 2020	BUY	$15.05 - $23.54 $2.14 Million - $3.35 Million	142,430 New	142,430 $2.31 Million
Q1 2020 Apr 09, 2020	SELL	$9.85 - $22.27 $687,037 - $1.55 Million	-69,750 Closed	0 $0
Q4 2019 Jan 09, 2020	BUY	$7.06 - $17.47 $492,435 - $1.22 Million	69,750 New	69,750 $1.14 Million

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sanders Morris Harris LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sanders Morris Harris LLC with notifications on news.

Account